

# '22년 3분기 경영실적

## Fact Sheet

2022. 11. 4.



## [제품별 매출액]

| 구분 (단위: 백만원)         | 3Q21           | 4Q21           | 1Q22           | 2Q22           | 3Q22           | YoY           | QoQ           |
|----------------------|----------------|----------------|----------------|----------------|----------------|---------------|---------------|
| <b>전문의약품</b>         | <b>50,571</b>  | <b>52,680</b>  | <b>51,725</b>  | <b>50,169</b>  | <b>52,753</b>  | <b>+4.3%</b>  | <b>+5.1%</b>  |
| - 순환기계               | 14,046         | 14,508         | 13,610         | 13,401         | 14,267         | +1.6%         | +6.5%         |
| - 마취제                | 7,487          | 7,931          | 6,610          | 8,460          | 10,041         | +34.1%        | +18.7%        |
| - 대사성                | 5,464          | 5,914          | 5,939          | 6,075          | 6,241          | +14.2%        | +2.7%         |
| - 소화기계               | 5,927          | 6,494          | 6,679          | 5,528          | 5,632          | -5.0%         | +1.9%         |
| - 점안제                | 3,118          | 2,550          | 2,884          | 2,264          | 1,941          | -37.7%        | -14.3%        |
| - 기타                 | 14,529         | 15,283         | 16,004         | 14,440         | 14,630         | +0.7%         | +1.3%         |
| <b>뷰티·웰빙</b>         | <b>38,290</b>  | <b>36,946</b>  | <b>41,381</b>  | <b>45,456</b>  | <b>44,600</b>  | <b>+16.5%</b> | <b>-1.9%</b>  |
| - 웰빙 / 비만 / 통증       | 20,298         | 19,898         | 18,415         | 23,615         | 21,740         | +7.1%         | -7.9%         |
| - 건강기능식품             | 11,960         | 12,698         | 14,314         | 16,882         | 16,936         | +41.6%        | +0.3%         |
| - 의료기기               | 3,746          | 2,559          | 6,433          | 3,089          | 4,013          | +7.1%         | +29.9%        |
| - 기타                 | 2,287          | 1,791          | 2,219          | 1,871          | 1,912          | -16.4%        | +2.2%         |
| <b>수탁(CMO)</b>       | <b>14,844</b>  | <b>16,450</b>  | <b>15,610</b>  | <b>19,225</b>  | <b>14,871</b>  | <b>+0.2%</b>  | <b>-22.6%</b> |
| - 점안제                | 7,619          | 7,771          | 7,317          | 8,138          | 6,951          | -8.8%         | -14.6%        |
| - 의약품                | 7,226          | 8,679          | 8,294          | 11,087         | 7,919          | +9.6%         | -28.6%        |
| <b>종속회사(휴온스푸드언스)</b> | <b>10,508</b>  | <b>9,314</b>   | <b>8,643</b>   | <b>10,397</b>  | <b>12,716</b>  | <b>+21.0%</b> | <b>+22.3%</b> |
| <b>연결조정</b>          | <b>-1,957</b>  | <b>-1,659</b>  | <b>-1,489</b>  | <b>-1,175</b>  | <b>-1,811</b>  | <b>+7.5%</b>  | <b>-54.2%</b> |
| <b>총 매출액</b>         | <b>112,257</b> | <b>113,732</b> | <b>115,870</b> | <b>124,074</b> | <b>123,129</b> | <b>+9.7%</b>  | <b>-0.8%</b>  |

## [연결포괄손익계산서]

| 구분 (단위: 백만원)     | 3Q21           | 4Q21           | 1Q22           | 2Q22           | 3Q22           | YoY            | QoQ           |
|------------------|----------------|----------------|----------------|----------------|----------------|----------------|---------------|
| <b>매출액</b>       | <b>112,257</b> | <b>113,732</b> | <b>115,870</b> | <b>124,074</b> | <b>123,129</b> | <b>+9.7%</b>   | <b>-0.8%</b>  |
| - 전문의약품          | 50,571         | 52,680         | 51,725         | 50,169         | <b>52,753</b>  | <b>+4.3%</b>   | <b>+5.1%</b>  |
| - 뷰티·웰빙          | 38,290         | 36,946         | 41,381         | 45,456         | <b>44,600</b>  | <b>+16.5%</b>  | <b>-1.9%</b>  |
| - 수탁(CMO)        | 14,844         | 16,450         | 15,610         | 19,225         | <b>14,871</b>  | <b>+0.2%</b>   | <b>-22.6%</b> |
| - 종속회사(휴온스푸디언스)  | 10,508         | 9,314          | 8,643          | 10,397         | <b>12,716</b>  | <b>+21.0%</b>  | <b>+22.3%</b> |
| - 연결 조정          | -1,957         | -1,659         | -1,489         | -1,175         | <b>-1,811</b>  | <b>+7.5%</b>   | <b>-54.2%</b> |
| 매출원가             | 47,926         | 50,122         | 50,288         | 57,078         | 57,633         | +20.3%         | +1.0%         |
| 매출총이익            | 64,331         | 63,610         | 65,581         | 66,995         | 65,496         | +1.8%          | -2.2%         |
| <b>판매비와관리비</b>   | <b>49,597</b>  | <b>59,248</b>  | <b>53,850</b>  | <b>56,125</b>  | <b>63,471</b>  | <b>+28.0%</b>  | <b>+13.1%</b> |
| 인건비              | 7,241          | 8,344          | 7,980          | 7,977          | 7,909          | +9.2%          | -0.8%         |
| 광고선전비            | 4,874          | 4,919          | 4,973          | 6,067          | 5,735          | +17.7%         | -5.5%         |
| 지급수수료            | 8,931          | 9,840          | 9,784          | 11,751         | 11,816         | +32.3%         | +0.6%         |
| 연구개발비            | 7,776          | 9,284          | 8,180          | 10,296         | 9,343          | +20.1%         | -9.3%         |
| 기타 판관비           | 20,774         | 26,860         | 22,934         | 20,035         | 28,668         | +38.0%         | +43.1%        |
| <b>영업이익</b>      | <b>14,734</b>  | <b>4,362</b>   | <b>11,732</b>  | <b>10,870</b>  | <b>2,025</b>   | <b>-86.3%</b>  | <b>-81.4%</b> |
| <b>영업이익률(%)</b>  | <b>13.1%</b>   | <b>3.8%</b>    | <b>10.1%</b>   | <b>8.8%</b>    | <b>1.6%</b>    | <b>-11.5%p</b> | <b>-7.1%p</b> |
| 지분법투자자산 관련손익     | -70            | -2,554         | 171            | 281            | 176            | +350.8%        | -37.2%        |
| 영업외손익            | 3,885          | -1,678         | -937           | -1,761         | 2,100          | -46.0%         | +219.2%       |
| 기타수익             | 2,001          | 897            | 472            | 1,164          | 5,225          | +161.1%        | +348.9%       |
| 기타비용             | 129            | 140            | 87             | 559            | 909            | +605.8%        | +62.6%        |
| 금융수익             | 3,924          | 1,792          | 1,149          | 920            | 1,035          | -73.6%         | +12.5%        |
| 금융비용             | 1,912          | 4,227          | 2,471          | 3,286          | 3,252          | +70.1%         | -1.0%         |
| 법인세비용차감전순이익      | 18,549         | 130            | 10,966         | 9,390          | 4,301          | -76.8%         | -54.2%        |
| 법인세비용            | 4,052          | 1,769          | 2,248          | 1,892          | 1,672          | -58.7%         | -11.6%        |
| <b>당기순이익</b>     | <b>14,497</b>  | <b>-1,639</b>  | <b>8,718</b>   | <b>7,498</b>   | <b>2,629</b>   | <b>-81.9%</b>  | <b>-64.9%</b> |
| <b>당기순이익률(%)</b> | <b>12.9%</b>   | <b>-1.4%</b>   | <b>7.5%</b>    | <b>6.0%</b>    | <b>2.1%</b>    | <b>-10.8%p</b> | <b>-3.9%p</b> |
| 지배주주순이익          | 14,282         | -1,025         | 8,728          | 7,612          | 2,327          | -83.7%         | -69.4%        |
| 비지배주주순이익         | 216            | -614           | -11            | -114           | 301            | +39.8%         | +364.6%       |

## [연결재무상태표]

| 구분 (단위: 백만원)      | FY 2020        | FY 2021        | 1Q22           | 2Q22           | 3Q22           |
|-------------------|----------------|----------------|----------------|----------------|----------------|
| <b>유동자산</b>       | <b>267,686</b> | <b>234,498</b> | <b>227,569</b> | <b>255,142</b> | <b>249,634</b> |
| 현금및현금성자산          | 26,933         | 57,277         | 34,373         | 37,775         | 44,524         |
| 유동성금융자산           | 92,850         | 12,850         | 24,000         | 46,610         | 51,020         |
| 매출채권              | 76,247         | 78,003         | 79,388         | 76,981         | 70,480         |
| 기타채권              | 3,356          | 14,737         | 14,636         | 15,106         | 5,504          |
| 재고자산              | 62,153         | 65,605         | 66,209         | 67,487         | 66,919         |
| 파생상품자산            |                |                |                | 1,611          | 1,611          |
| 기타유동자산            | 6,147          | 6,027          | 8,963          | 9,572          | 9,577          |
| <b>비유동자산</b>      | <b>148,816</b> | <b>202,399</b> | <b>212,762</b> | <b>216,146</b> | <b>218,317</b> |
| 장기성기타채권           | 1,720          | 2,166          | 2,273          | 1,765          | 2,138          |
| 비유동성금융자산          | 28,561         | 37,700         | 36,223         | 34,751         | 33,249         |
| 종속/관계기업투자         | 5,096          | 6,587          | 6,891          | 7,274          | 7,714          |
| 유형자산              | 98,691         | 129,696        | 138,979        | 145,883        | 149,269        |
| 무형자산              | 5,401          | 5,743          | 5,421          | 4,594          | 3,634          |
| 사용권자산             | 2,321          | 9,179          | 10,326         | 9,839          | 9,209          |
| 기타비유동자산           | 6,547          | 8,090          | 7,879          | 6,484          | 6,542          |
| 이연법인세자산           | 478            | 3,237          | 4,771          | 5,555          | 6,562          |
| <b>자산총계</b>       | <b>416,501</b> | <b>436,898</b> | <b>440,331</b> | <b>471,288</b> | <b>467,951</b> |
| <b>유동부채</b>       | <b>125,041</b> | <b>147,522</b> | <b>148,194</b> | <b>139,691</b> | <b>118,241</b> |
| 매입채무              | 9,709          | 14,309         | 14,810         | 14,451         | 13,266         |
| 기타채무              | 7,546          | 12,384         | 9,702          | 7,454          | 8,877          |
| 단기차입금             | 61,000         | 29,000         | 29,000         | 29,000         | 10,000         |
| 당기법인세부채           | 6,344          | 8,042          | 8,238          | 5,958          | 3,155          |
| 전환사채(유동)          | 0              | 35,969         | 36,750         | 37,538         | 38,336         |
| 환불부채              | 3,945          | 3,994          | 4,544          | 4,630          | 4,871          |
| 유동성장기차입금          | 0              | 0              | 194            | 194            | 194            |
| 유동성전환상환우선주부채      | 0              | 3,208          | 0              | 0              | 0              |
| 파생상품부채            | 17,763         | 19,272         | 16,238         | 17,850         | 17,850         |
| 유동성리스부채           | 1,174          | 2,659          | 2,810          | 2,842          | 2,748          |
| 기타유동성부채           | 17,561         | 18,684         | 25,907         | 19,773         | 18,945         |
| <b>비유동부채</b>      | <b>47,956</b>  | <b>18,741</b>  | <b>19,818</b>  | <b>51,368</b>  | <b>66,041</b>  |
| 장기차입금             | 0              | 487            | 620            | 32,620         | 47,826         |
| 전환사채              | 33,030         | 0              | 0              | 0              | 0              |
| 기타비유동부채           | 9,324          | 10,002         | 9,906          | 9,917          | 9,867          |
| 리스부채              | 1,220          | 6,569          | 7,574          | 7,076          | 6,557          |
| 전환상환우선주부채         | 4,381          | 1,682          | 1,718          | 1,755          | 1,791          |
| <b>부채총계</b>       | <b>172,997</b> | <b>166,262</b> | <b>168,012</b> | <b>191,058</b> | <b>184,282</b> |
| <b>지배기업 소유주지분</b> | <b>238,797</b> | <b>266,093</b> | <b>267,471</b> | <b>275,492</b> | <b>278,604</b> |
| 자본금               | 4,940          | 5,430          | 5,968          | 5,968          | 5,968          |
| 자본잉여금             | 73,659         | 73,659         | 71,886         | 71,886         | 71,882         |
| 자본조정              | -8,341         | -6,506         | -5,730         | -5,398         | -4,809         |
| 기타포괄손익누계액         | 979            | 1,275          | 1,376          | 1,454          | 1,654          |
| 이익잉여금             | 167,560        | 192,235        | 193,970        | 201,582        | 203,909        |
| <b>비지배지분</b>      | <b>4,707</b>   | <b>4,542</b>   | <b>4,849</b>   | <b>4,738</b>   | <b>5,065</b>   |
| <b>자본총계</b>       | <b>243,504</b> | <b>270,635</b> | <b>272,320</b> | <b>280,230</b> | <b>283,669</b> |
| <b>자본과부채총계</b>    | <b>416,501</b> | <b>436,898</b> | <b>440,331</b> | <b>471,288</b> | <b>467,951</b> |